JNJ 56021927

Phase 1Small molecule

AAragon Pharmaceuticals, Inc.

JNJ 56021927 is one of 54 small molecule programs targeting Prostate Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Prostatic Neoplasms, Castration-ResistantActive, not recruiting

Prostatic NeoplasmsActive, not recruiting

Prostate CancerPhase 1

Active, not recruiting

Prostatic Neoplasms, Castration-ResistantPhase 1

Active, not recruiting

Prostatic NeoplasmsPhase 1

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

Mekinist

Novartis

Preclinical

3 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Duragesic

CCephalon

Preclinical

1 6

Prednisone/prednisolone

Roche

Preclinical

3 7

Triptorelin Pamoate

Ipsen

Preclinical

2 8

Ifex

BBaxter Healthcare Corporation

Xylocaine

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Active, not recruiting

Prostatic Neoplasms, Castration-Resistant

NCT02592317

Phase 1Active, not recruiting

Prostatic Neoplasms

NCT02123758

Clinical

Trials by Indication[1]

Moderate Hepatic Impairment1 trial

A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function

Completed·AAragon Pharmaceuticals, Inc.·Phase 1·NCT02524717·24 enrolled

Prostate Cancer1 trial

A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02162836·6 enrolled

Interaction1 trial

Study to Assess Drug-Drug Interaction Between Itraconazole or Gemfibrozil and JNJ-56021927

Completed·AAragon Pharmaceuticals, Inc.·Phase 1·NCT02230033·45 enrolled

Prostatic Neoplasms, Castration-Resistant1 trial

Drug-drug Interaction Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Subjects With Castration-Resistant Prostate Cancer

Active, not recruiting·AAragon Pharmaceuticals, Inc.·Phase 1·NCT02592317·23 enrolled

Prostatic Neoplasms1 trial

A Drug-Drug Interaction, Safety and Efficacy Study With JNJ-56021927 (ARN-509) and Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting·AAragon Pharmaceuticals, Inc.·Phase 1·NCT02123758·57 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for JNJ 56021927. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JNJ 56021927 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JNJ 56021927. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aragon Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAragon Pharmaceuticals, Inc.

JNJ 56021927

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Moderate Hepatic Impairment1 trial

Prostate Cancer1 trial

Interaction1 trial

Prostatic Neoplasms, Castration-Resistant1 trial

Prostatic Neoplasms1 trial

References

Drug Info

Quick Facts

Related News